C. Hiew
Geelong Football Club
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C. Hiew.
American Journal of Cardiology | 2018
S. Biswas; S. Duffy; Jeffrey Lefkovits; Nick Andrianopoulos; A. Brennan; A. Walton; William Chan; S. Noaman; James Shaw; L. Dawson; Andrew E. Ajani; David J. Clark; Melanie Freeman; C. Hiew; E. Oqueli; Christopher M. Reid; Dion Stub
Over the last decade, systems of care for ST-elevation myocardial infarction (STEMI) have evolved to try to improve outcomes and timely access to percutaneous coronary intervention (PCI). There have also been advances in PCI techniques and adjunctive pharmacotherapies. In this study, we sought to determine temporal changes in practices and clinical outcomes of PCI in patients with STEMI. We prospectively collected data on 8,412 consecutive patients undergoing PCI for STEMI between 2005 and 2016 in the multicenter Melbourne Interventional Group registry. Data were divided by procedure year for trends analysis. The primary end point was 30-day mortality. Patient demographics and comorbidities including smoking and diabetes have remained stable. The volume of primary PCI performed within 12 hours of symptom onset has significantly risen (65.7% to 80.1%, p < 0.01). The proportion of patients achieving the recommended door-to-balloon time ≤90 minutes has also risen (37.6% to 59.0%, p < 0.01). Patient complexity has also increased with more patients after out-of-hospital cardiac arrest with STEMI now being treated with PCI (2.6% to 9.1%, p < 0.01). A shift from mainly femoral to radial access and from bare-metal to drug-eluting stent use was seen. Glycoprotein IIb/IIIa inhibitors are being used less frequently with increasing use of newer antiplatelet agents. Thirty-day mortality has remained low throughout the study period at 6.5% overall. In conclusion, although timely access to primary PCI has improved, mortality rates have remained unchanged, but remain low and compare favorably with international data. Australian PCI practice has overall evolved in response to evidence and emergence of new adjunctive device and pharmacotherapies.
BMJ Open | 2017
M. Yudi; Omar Farouque; Nick Andrianopoulos; Andrew E. Ajani; Katie Kalten; A. Brennan; Jeffrey Lefkovits; C. Hiew; E. Oqueli; Christopher M. Reid; S. Duffy; David J. Clark
Objective We aim to ascertain the prognostic significance of persistent smoking and smoking cessation after an acute coronary syndrome (ACS) in the era of percutaneous coronary intervention (PCI) and optimal secondary prevention pharmacotherapy. Methods Consecutive patients from the Melbourne Interventional Group registry (2005–2013) who were alive at 30 days post-ACS presentation were included in our observational cohort study. Patients were divided into four categories based on their smoking status: non-smoker; ex-smoker (quit >1 month before ACS); recent quitter (smoker at presentation but quit by 30 days) and persistent smoker (smoker at presentation and at 30 days). The primary endpoint was survival ascertained through the Australian National Death Index linkage. A Cox-proportional hazards model was used to estimate the adjusted HR and 95% CI for survival. Results Of the 9375 patients included, 2728 (29.1%) never smoked, 3712 (39.6%) were ex-smokers, 1612 (17.2%) were recent quitters and 1323 (14.1%) were persistent smokers. Cox-proportional hazard modelling revealed, compared with those who had never smoked, that persistent smoking (HR 1.78, 95% CI 1.36 to 2.32, p<0.001) was an independent predictor of increased hazard (mean follow-up 3.9±2.2 years) while being a recent quitter (HR 1.27, 95% CI 0.96 to 1.68, p=0.10) or an ex-smoker (HR 1.03, 95% CI 0.87 to 1.22, p=0.72) were not. Conclusions In a contemporary cohort of patients with ACS, those who continued to smoke had an 80% risk of lower survival while those who quit had comparable survival to lifelong non-smokers. This underscores the importance of smoking cessation in secondary prevention despite the improvement in management of ACS with PCI and pharmacotherapy.
International Journal of Cardiology | 2016
M. Yudi; J. Ramchand; Omar Farouque; Nick Andrianopoulos; William Chan; S. Duffy; Jeffrey Lefkovits; A. Brennan; Ryan Spencer; Dharsh Fernando; C. Hiew; Melanie Freeman; Christopher M. Reid; Andrew E. Ajani; David J. Clark
BACKGROUND Door-to-balloon time (DTBT) less than 90min remains the benchmark of timely reperfusion in ST-elevation myocardial infarction (STEMI). The relative long-term benefit of timely reperfusion in STEMI patients with differing risk profiles is less certain. Thus, we aimed to assess the impact of DTBT on long-term mortality in high- and low-risk STEMI patients. METHOD We analysed baseline clinical and procedural characteristics of 2539 consecutive STEMI patients who underwent primary percutaneous coronary intervention (PCI) from the Melbourne Interventional Group registry from 2004 to 2012. Patients were classified high risk (HR-STEMI) if they presented with cardiogenic shock, out-of-hospital cardiac arrest (OHCA) or Killip class ≥2; or low-risk (LR-STEMI) if there were no high-risk features. We then stratified high- and low-risk patients by DTBT (≤90min vs. >90min) and assessed long-term mortality. RESULT Of the 2539 patients, 395 (16%) met the high-risk criteria. A DTBT ≤90min was achieved in 43% of HR-STEMI patients and in 55% of LR-STEMI patients. Patients in the HR-STEMI compared to LR-STEMI cohort had higher in-hospital (31% vs. 1%, p<0.01) and long-term mortality (37% vs. 7%, p<0.01). A DTBT ≤90min was associated with significant improvements in short- and long-term mortality in both groups. A DTBT ≤90min was an independent multivariate predictor of long-term survival in LR-STEMI (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.3-0.9, p=0.02) but not in HR-STEMI (HR 0.7, 95% CI 0.5-1.1, p=0.11). CONCLUSION A DTBT ≤90min was associated with improved short- and long-term outcomes in high- and low-risk STEMI patients. However, it was only an independent predictor of long-term survival in LR-STEMI patients.
American Journal of Cardiology | 2017
M. Yudi; Garry Hamilton; Omar Farouque; Nick Andrianopoulos; S. Duffy; Jeffrey Lefkovits; A. Brennan; Dharsh Fernando; C. Hiew; Melanie Freeman; Christopher M. Reid; Robynne Dakis; Andrew E. Ajani; David J. Clark
Guidelines strongly recommend patients with ST-elevation myocardial infarction (STEMI) receive timely mechanical reperfusion, defined as door-to-balloon time (DTBT) ≤90 minutes. The impact of timely reperfusion on clinical outcomes in patients aged 75-84 and ≥85 years is uncertain. We analysed 2,972 consecutive STEMI patients who underwent primary percutaneous coronary intervention from the Melbourne Interventional Group Registry (2005-2014). Patients aged <75 years were included in the younger group, those aged 75-84 years were in the elderly group and those ≥85 years were in the very elderly group. The primary endpoints were 12-month mortality and major adverse cardiovascular events (MACE). 2,307 (77.6%) patients were <75 years (mean age 59 ± 9 years), 495 (16.7%) were 75-84 years and 170 (5.7%) were ≥85 years. There has been a significant decrease in DTBT over 10 years in younger and elderly patients (p-for-trend <0.01 and 0.03) with a trend in the very elderly (p-for-trend 0.08). Compared to younger and elderly patients, the very elderly had higher 12-month mortality (3.6% vs 10.7% vs. 29.4%; p = 0.001) and MACE (10.8% vs 20.6% vs 33.5%; p = 0.001). DTBT ≤90 minutes was associated with improved outcomes on univariate analysis but was not an independent predictor of improved 12-month mortality (OR 0.84, 95% CI 0.54-1.31) or MACE (OR 0.89, 95% CI 0.67-1.16). In conclusion, over a 10-year period, there was an improvement in DTBT in patients aged <75 years and 75-84 years however DTBT ≤90 minutes was not an independent predictor of 12-month outcomes. Thus assessing whether patients aged ≥85 years are suitable for invasive management does not necessarily translate to worse clinical outcomes.
Journal of the American College of Cardiology | 2016
L. Roberts; S. Parfrey; Nick Andrianopoulos; A. Teh; A. Brennan; C. Hiew; David J. Clark; S. Duffy; Andrew E. Ajani; Christopher M. Reid; Melanie Freeman
There is increasing evidence that low-risk patients with STEMI can be safely discharged at ≤72hours from admission. Early discharge post STEMI is not guideline based, and patients frequently remain hospitalised for >72hours, utilising hospital beds and resources. Utilising a large multicentre
Journal of the American College of Cardiology | 2016
M. Yudi; Nick Andrianopoulos; Jessica O'Brien; Laura Selkrig; David J. Clark; Andrew E. Ajani; C. Hiew; William Chan; Christopher M. Reid; Omar Farouque; Anthony M. Dart; S. Duffy
Recurrent acute coronary syndrome (ACS) hospitalisations and unplanned revascularisations are common and costly after acute myocardial infarction (MI). There is a paucity of data describing predictors of such events. Consecutive patients from the Melbourne Interventional Group registry (2005-2014)
Asian Cardiovascular and Thoracic Annals | 2016
Cheng He; Reny Suryani; C. Hiew; Andrew Cheng; Bo Zhang
Pericardiectomy is the only definitive treatment option for patients with constrictive pericarditis. We present the case of a 67-year-old man who developed new moderate to severe mitral regurgitation following phrenic nerve-to-phrenic nerve pericardiectomy for constrictive pericarditis. The severity of the regurgitation was followed up by serial echocardiography which showed improvement 19 days later and complete resolution at 9 months after surgery. Potential mechanisms explaining the evolution of this mitral valve dysfunction in the setting of pericardiectomy are postulated.
Heart Lung and Circulation | 2017
S. Biswas; D. Dinh; A. Brennan; M. Tacey; Nick Andrianopoulos; R. Brien; J. Gutman; A. MacIsaac; C. Hiew; M. Rowe; R. Dick; J. Amerena; N. Nadarajah; Danny Liew; Dion Stub; J. Lefkovits; Christopher A. Reid
Heart Lung and Circulation | 2018
B. Khialani; Nick Andrianopoulos; T. Yip; Andrew E. Ajani; M. Yudi; Melanie Freeman; C. Jaworski; E. Oqueli; A. Brennan; S. Duffy; A. Hutchison; C. Hiew; M. Sebastian; Dion Stub
Heart Lung and Circulation | 2018
M. Tacey; D. Dinh; A. Brennan; Nick Andrianopoulos; E. Zomer; J. Gutman; A. MacIsaac; C. Hiew; M. Rowe; J. Senior; J. Amerena; Danny Liew; A. Wilson; Christopher A. Reid; Dion Stub; J. Lefkovits